• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多中心评价晚期卵巢癌行最佳肿瘤细胞减灭术后的术后发病率和死亡率。

Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer.

机构信息

Institut Claudius Regaud, Toulouse, France.

出版信息

PLoS One. 2012;7(7):e39415. doi: 10.1371/journal.pone.0039415. Epub 2012 Jul 23.

DOI:10.1371/journal.pone.0039415
PMID:22844394
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3402488/
Abstract

PURPOSE

While optimal cytoreduction is the standard of care for advanced ovarian cancer, the related post-operative morbidity has not been clearly documented outside pioneering centers. Indeed most of the studies are monocentric with inclusions over several years inducing heterogeneity in techniques and goals of surgery. We assessed the morbidity of optimal cytoreduction surgery for advanced ovarian cancer within a short inclusion period in 6 referral centers dedicated to achieve complete cytoreduction.

PATIENTS AND METHODS

The 30 last optimal debulking surgeries of 6 cancer centers were included. Inclusion criteria included: stage IIIc- IV ovarian cancer and optimal surgery performed at the site of inclusion. All post-operative complications within 30 days of surgery were recorded and graded using the Memorial secondary events grading system. Student-t, Chi2 and non-parametric statistical tests were performed.

RESULTS

180 patients were included. There was no demographic differences between the centers. 63 patients underwent surgery including intestinal resections (58 recto-sigmoid resection), 24 diaphragmatic resections, 17 splenectomies. 61 patients presented complications; One patient died post-operatively. Major (grade 3-5) complications requiring subsequent surgeries occurred in 21 patients (11.5%). 76% of patients with a major complication had undergone an ultraradical surgery (P = 0.004).

CONCLUSION

While ultraradical surgery may result in complete resection of peritoneal disease in advanced ovarian cancer, the associated complication rate is not negligible. Patients should be carefully evaluated and the timing of their surgery optimized in order to avoid major complications.

摘要

目的

虽然理想的肿瘤细胞减灭术是晚期卵巢癌的标准治疗方法,但相关的术后发病率在先驱中心之外并没有得到明确记录。事实上,大多数研究都是单中心的,多年来的纳入导致了手术技术和目标的异质性。我们评估了在 6 个专门致力于实现完全肿瘤细胞减灭术的转诊中心内,在短时间纳入期内对晚期卵巢癌进行理想肿瘤细胞减灭术的发病率。

患者和方法

纳入了 6 个癌症中心的最后 30 例最佳肿瘤细胞减灭术。纳入标准包括:IIIc-IV 期卵巢癌和在纳入地点进行的最佳手术。记录了手术后 30 天内所有的术后并发症,并使用 Memorial 次要事件分级系统进行分级。进行了学生 t 检验、卡方检验和非参数统计检验。

结果

共纳入 180 例患者。各中心之间无人口统计学差异。63 例患者接受了包括肠切除术(58 例直肠乙状结肠切除术)、24 例膈切除术、17 例脾切除术在内的手术。61 例患者出现并发症;1 例患者术后死亡。21 例患者发生需要后续手术的主要(3-5 级)并发症(11.5%)。有主要并发症的患者中 76%接受了超根治性手术(P = 0.004)。

结论

虽然超根治性手术可能导致晚期卵巢癌的腹膜疾病完全切除,但相关的并发症发生率不容忽视。应仔细评估患者,并优化手术时机,以避免主要并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/3402488/31abbe7ca829/pone.0039415.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/3402488/fabaaa5148e7/pone.0039415.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/3402488/31abbe7ca829/pone.0039415.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/3402488/fabaaa5148e7/pone.0039415.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d0c/3402488/31abbe7ca829/pone.0039415.g002.jpg

相似文献

1
Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer.多中心评价晚期卵巢癌行最佳肿瘤细胞减灭术后的术后发病率和死亡率。
PLoS One. 2012;7(7):e39415. doi: 10.1371/journal.pone.0039415. Epub 2012 Jul 23.
2
Ultra-radical surgery for advanced ovarian cancer: a retrospective cohort study in a tertiary referral cancer center in the UK.英国一家三级转诊癌症中心的一项回顾性队列研究:晚期卵巢癌的超根治性手术。
Minerva Obstet Gynecol. 2024 Aug;76(4):319-326. doi: 10.23736/S2724-606X.22.05179-X. Epub 2023 Apr 14.
3
Post-operative pancreatic fistula following splenectomy with or without distal pancreatectomy at cytoreductive surgery in advanced ovarian cancer.在卵巢癌的细胞减灭术中,行脾切除加或不加胰体尾部切除术,术后可能出现胰腺瘘。
Int J Gynecol Cancer. 2020 Jul;30(7):1043-1051. doi: 10.1136/ijgc-2020-001312. Epub 2020 Jun 16.
4
Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.在日常实践中,FIGO 分期 IIIC 至 IV 期卵巢、输卵管和腹膜癌患者的最大减瘤术:一项回顾性法国多中心研究。
Int J Gynecol Cancer. 2012 Oct;22(8):1337-43. doi: 10.1097/IGC.0b013e31826a3559.
5
A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.采取激进的方法实现完全肿瘤细胞减灭术,可提高晚期卵巢癌患者的生存率。
J Visc Surg. 2020 Apr;157(2):79-86. doi: 10.1016/j.jviscsurg.2019.12.002. Epub 2019 Dec 16.
6
Short- and long-term morbidity of total parietal peritonectomy for advanced ovarian cancer.全腹膜外肿瘤廓清术治疗晚期卵巢癌的近期和远期发病率。
Int J Gynecol Cancer. 2023 Nov 6;33(11):1771-1777. doi: 10.1136/ijgc-2023-004742.
7
Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.晚期卵巢癌的积极手术策略:一项针对203例IIIC期和IV期患者的单中心研究。
Eur J Surg Oncol. 2009 Feb;35(2):135-43. doi: 10.1016/j.ejso.2008.01.005. Epub 2008 Mar 4.
8
Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.减瘤手术联合器官切除治疗晚期卵巢癌。
Int J Clin Oncol. 2003 Apr;8(2):90-6. doi: 10.1007/s101470300016.
9
Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer.膈肌手术作为晚期卵巢癌细胞减灭术一部分的相关性研究
In Vivo. 2018 Mar-Apr;32(2):431-436. doi: 10.21873/invivo.11258.
10
Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity.原发性卵巢癌外科减瘤术中低体温:危险因素及其与术后发病率的关系。
Gynecol Oncol. 2013 Dec;131(3):525-30. doi: 10.1016/j.ygyno.2013.08.034. Epub 2013 Sep 7.

引用本文的文献

1
The impact of preoperative immunonutritional status on postoperative complications in ovarian cancer.术前免疫营养状况对卵巢癌术后并发症的影响。
J Ovarian Res. 2025 Apr 29;18(1):88. doi: 10.1186/s13048-025-01624-3.
2
Assessment of the American College of Surgeons Surgical Risk Calculator (ACS-SRC) for Prediction of Early Postoperative Complications in Patients Undergoing Cytoreductive Surgery for Ovarian Peritoneal Carcinomatosis.美国外科医师学会手术风险计算器(ACS-SRC)对接受卵巢腹膜癌减瘤手术患者术后早期并发症预测的评估。
Curr Oncol. 2024 Dec 7;31(12):7863-7871. doi: 10.3390/curroncol31120579.
3
Clinical value of serum tumor markers in assessing the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: single-center prospective clinical study.

本文引用的文献

1
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.2010 年妇科癌症国际协作组(GCIG)卵巢癌临床试验共识声明:第四届卵巢癌共识会议报告。
Int J Gynecol Cancer. 2011 May;21(4):750-5. doi: 10.1097/IGC.0b013e31821b2568.
2
Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases.晚期卵巢癌膈肌手术的发病率:148例回顾性研究
Eur J Surg Oncol. 2011 Feb;37(2):175-80. doi: 10.1016/j.ejso.2010.10.004. Epub 2010 Nov 18.
3
Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.
血清肿瘤标志物在评估晚期卵巢癌新辅助化疗疗效中的临床价值:单中心前瞻性临床研究
Front Oncol. 2024 May 28;14:1399502. doi: 10.3389/fonc.2024.1399502. eCollection 2024.
4
Characteristics, Treatment Patterns and Survival of International Federation of Gynecology and Obstetrics Stage IV Epithelial Ovarian Cancer-A Population-Based Study.国际妇产科联盟IV期上皮性卵巢癌的特征、治疗模式及生存情况——一项基于人群的研究
Cancers (Basel). 2023 Nov 30;15(23):5676. doi: 10.3390/cancers15235676.
5
The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series.中性氩等离子体与电凝对晚期卵巢癌组织的影响:一项病例系列研究。
J Ovarian Res. 2022 Dec 29;15(1):140. doi: 10.1186/s13048-022-01070-5.
6
Rectosigmoid sparing en bloc pelvic resection for fixed ovarian tumors: Surgical technique and perioperative and oncologic outcomes.保留直肠乙状结肠的整块盆腔切除术治疗固定性卵巢肿瘤:手术技术及围手术期和肿瘤学结局
Front Oncol. 2022 Aug 22;12:980050. doi: 10.3389/fonc.2022.980050. eCollection 2022.
7
Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis.预测卵巢癌细胞减灭术后术后发病率的因素:系统评价和荟萃分析。
J Gynecol Oncol. 2022 Jul;33(4):e53. doi: 10.3802/jgo.2022.33.e53. Epub 2022 Jun 7.
8
Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network.晚期低级别浆液性卵巢癌的手术意义:妇科罕见恶性肿瘤网络数据库分析
Cancers (Basel). 2022 May 9;14(9):2345. doi: 10.3390/cancers14092345.
9
Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team.直肠乙状结肠切除术在 IIIC-IV 期卵巢癌内脏腹膜廓清术中的应用:妇科肿瘤组与结直肠组的发病率比较。
J Gynecol Oncol. 2021 May;32(3):e42. doi: 10.3802/jgo.2021.32.e42.
10
Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.基于纪念斯隆·凯特琳虚弱指数的虚弱与老年卵巢癌女性的手术决策、临床试验参与和总体生存相关。
Gynecol Oncol. 2021 Jun;161(3):687-692. doi: 10.1016/j.ygyno.2021.03.016. Epub 2021 Mar 25.
识别传统卵巢癌治疗方法中风险最高的患者群体。
Gynecol Oncol. 2011 Jan;120(1):23-8. doi: 10.1016/j.ygyno.2010.09.010. Epub 2010 Oct 8.
4
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.新辅助化疗与初始肿瘤细胞减灭术用于 IIIC 或 IV 期卵巢癌。
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
5
Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.最大程度的初次细胞减灭术在晚期上皮性卵巢癌和输卵管癌患者中的作用:手术和肿瘤学结果。单机构经验。
Gynecol Oncol. 2010 Nov;119(2):259-64. doi: 10.1016/j.ygyno.2010.07.032. Epub 2010 Aug 25.
6
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.广泛上腹部手术在原发性卵巢癌、输卵管癌和腹膜癌肿瘤细胞减灭术中的主要并发症发生率。
Gynecol Oncol. 2010 Oct;119(1):38-42. doi: 10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.
7
Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer.比较腹膜癌病评分方法在预测晚期卵巢癌可切除性和预后中的作用。
Am J Obstet Gynecol. 2010 Feb;202(2):178.e1-178.e10. doi: 10.1016/j.ajog.2009.10.856.
8
Quality of care in advanced ovarian cancer: the importance of provider specialty.晚期卵巢癌的护理质量:提供者专业的重要性。
Gynecol Oncol. 2010 Apr;117(1):18-22. doi: 10.1016/j.ygyno.2009.12.033. Epub 2010 Jan 27.
9
Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.新辅助化疗能否提高晚期卵巢癌的最佳肿瘤细胞减灭率?21项研究的荟萃分析
Ann Surg Oncol. 2009 Aug;16(8):2315-20. doi: 10.1245/s10434-009-0558-6. Epub 2009 Jun 11.
10
Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer.Ⅲ/Ⅳ期卵巢癌膈肌手术的肺部并发症
BJOG. 2009 Jul;116(8):1062-8. doi: 10.1111/j.1471-0528.2009.02214.x. Epub 2009 May 14.